Application of microarray technology in psychotropic drug trials

Journal of Psychopharmacology

Volumn 20, Issue 4 SUPPL., 2006, Pages 72-78

  Murphy Jr , Greer M ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Depression; Genotyping; Microarray; Pharmacogenetics; Psychotropic

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; DEBRISOQUINE HYDROXYLASE; MIRTAZAPINE; NORTRIPTYLINE; OXYGENASE; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CYP2D6 GENE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER METABOLISM; MAJOR DEPRESSION; MICROARRAY ANALYSIS; ORTHOSTATIC DIZZINESS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 33750079595     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806066059     Document Type: Article

References (63)

1. Bell P A, Chaturvedi S, Gelfand C A, Huang C Y, Kochersperger M, Kopla R, Modica F, Pohl M, Varde S, Zhao R, Zhao X, Boyce-Jacino M T, Yassen A (2002) SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drag discovery. Biotechniques June (suppl): 70-72, 74, 76-77
2. Bertilsson L, Dahl M L, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53: 111-122
3. Bertilsson L, Mellstrom B, Sjokvist F, Martenson B, Asberg M (1981) Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1: 560-561
4. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Schulz H U, Sjoqvist F (1980) Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 27: 1673-1677
5. Blangero J (2004) Localization and identification of human quantitative trait loci: King Harvest has surely come. Current Opinion in Genetics and Development 14: 233-240
6. Blazer D G (2003) Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 58: 249-265
7. Botstein D, Risch N (2003) Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 33 (suppl.): 228-237
8. Carlson C S, Eberle M A, Rieder M J, Smith J D, Kraglyak L, Nickerson D A (2003) Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 33: 518-521
9. Carlson C S, Eberle M A, Rieder M J, Yi Q, Kruglyak L, Nickerson D A (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120
10. Chou W H, Yan F X, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder T B, Liu W W, Teiling C, Wedlund P J (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20: 246-251
11. Cidis Meltzer C, Drevets W C, Price J C, Mathis C A, Lopresti B, Greer P J, Villemagne V L, Holt D, Mason N S, Houck P R, Reynolds C F III, DeKosky S T (2001) Gender-specific ageing effects on the serotonin 1A receptor. Brain Res 895: 9-17
12. Claassen J D, Pascoe N, Schatzberg A F, Murphy G M, Jr. (2001) Rapid detection of the C-1496G polymorphism in the CYP2D6 *2 allele. Clin Chem 47: 2153-2155
13. Dalen P, Dahl M L, Ruiz M L, Nordin J, Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63: 444-452
14. Daly A K, Brockmoller J, Broly F, Eichelbaum M, Evans W E, Gonzalez F J, Huang J D, Idle J R, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer U A, Nebert DW, Steen V M, Wolf C R, Zanger U M (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201
15. de Leon J, Susce M T, Pan R M, Fairchild M, Koch W H, Wedlund P J (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27
16. Dunner D L (2003) Treatment considerations for depression in the elderly. CNS Spectr 8: 14-19
17. Ewis A A, Zhelev Z, Bakalova R, Fukuoka S, Shinohara Y, Ishikawa M, Baba Y (2005) A history of microarrays in biomedicine. Expert Review of Molecular Diagnostics J: 315-328
18. Faham M, Zheng J, Moorhead M, Fakhrai-Rad H, Namsaraev E, Wong K, Wang Z, Chow SG, Lee L, Suyenaga K, Reichert J, Boudreau A, Eberle J, Bruckner C, Jain M, Karlin-Neumann G, Jones H B, Willis T D, Buxbaum J D, Davis R W (2005) Multiplexed variation scanning for 1,000 amplicons in hundreds of patients using mismatch repair detection (MRD) on tag arrays. PNAS 102: 14717-14722
19. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J (1999) Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47: 450-453
20. Groleau G, Jotte R, Barish R (1990) The electrocardiographic manifestations of cyclic antidepressant therapy and overdose: a review. The Journal of Emergency Medicine 8: 597-605
21. Gunderson K L, Steemers F J, Lee G, Mendoza L G, Chee M S (2005) A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 37: 549-554
22. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296
23. Hinds D A, Stuve L L, Nilsen G B, Halperin E, Eskin E, Ballinger D G, Frazer K A, Cox D R (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307: 1072-1079
24. Hirschhorn J N, Daly M J (2005) Genome-wide association studies for common diseases and complex traits. Nat Rev Genet 6: 95-108
25. Johansson I, Lundqvist E, Bertilsson L, Dahl M L, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 90: 11825-11829
26. Jongenelis K, Pot A M, Eisses A M H, Beekman A T F, Kluiter H, Ribbe M W (2004) Prevalence and risk indicators of depression in elderly nursing home patients: the AGED study. Journal of Affective Disorders 83: 135-142
27. Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J (2005) Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20: 71-78
28. Ke X, Miretti M M, Broxholme J, Hunt S, Beck S, Bentley D R, Deloukas P, Cardon L R (2005) A comparison of tagging methods and their tagging space. Hum Mol Genet 14: 2757-2767
29. Kirchheiner J, Henckel H B, Meineke I, Roots I, Brockmoller J (2004) Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 24: 647-652
30. Kwok P Y (2001) Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet 2: 235-258
31. Lohmueller K E, Pearce C L, Pike M, Lander E S, Hirschhorn J N (2003) Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 33: 177-182
32. Lovlie R, Daly A K, Molven A, Idle J R, Steen V M (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392: 30-34
33. Malhotra A K, Murphy G M, Jr., Kennedy J L (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780-796
34. Marez D, Legrand M, Sabbagh N, Guidice J M, Spire C, Lafitte J J, Meyer U A, Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193-202
35. Meltzer C C, Smith G, Price J C, Reynolds C F III, Mathis C A, Greer P, Lopresti B, Mintun M A, Pollock B G, Ben-Eliezer D, Cantwell M N, Kaye W, DeKosky S T (1998) Reduced binding of [18F]altanserin to serotonin type 2A receptors in ageing: persistence of effect after partial volume correction. Brain Res 813: 167-171
36. Murphy G M Jr, Kremer C, Rodrigues H E, Schatzberg A F (2003) Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 760: 1830-1835
37. Murphy G M Jr, Hollander S B, Rodrigues H E, Kremer C, Schatzberg A F (2004) Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61: 1163-1169
38. Murphy G M Jr, Pollock B G, Kirshner M A, Pascoe N, Cheuk W, Mulsant B H, Reynolds C F III (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25: 737-743
39. Palmer L J, Lyle J, Cardon L R, Lon R (2005) Shaking the tree: mapping complex disease genes with linkage disequilibrium. Lancet 366: 1223-1234
40. Pritchard J K, Cox N J (2002) The allelic architecture of human disease genes: common disease-common variant ... or not? Hum Mol Genet 11: 2417-2423
41. Raimundo S, Fischer J, Eichelbaum M, Griese E U, Schwab M, Zanger U M (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10: 577-581
42. Rebbeck T R, Spitz M, Wu X (2004) Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5: 589-597
43. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295
44. Schatzberg A F, Cole JO, DeBattista C (2003) Manual of Clinical Psychopharmacology, 4th edn. American Psychiatric Publishing, Arlington, VA
45. Schatzberg A F, Kremer C, Rodrigues H E, Murphy G M Jr (2002) Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 10:541-550
46. Sheline Y I (2003) Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54: 338-352
47. Siddiqui A, Kerb R, Weale M E, Brinkmann U, Smith A, Goldstein D B, Wood N W, Sisodiya S M (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348: 1442-1448
48. Sindrup S H, Brosen K, Gram L F, Hallas J, Skjelbo E, Allen A, Allen G D, Cooper S M, Mellows G, Tasker T C, Zussman B D (1992a) Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 57: 288-295
49. Sindrup S H, Brosen K, Gram L F, Hallas J, Skjelbo E, Allen A, Allen G D, Cooper S M, Mellows G, Tasker T C (1992b) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 57: 278-287
50. Solai L K, Pollock B G, Mulsant B H, Frye R F, Miller M D, Sweet R A, Kirshner M, Sorisio D, Begley A, Reynolds C F III (2002) Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 22: 481-486
51. Stahl S M (1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 57: 215-235
52. Steen V M, Andreassen O A, Daly A K, Tefre T, Borresen A L, Idle J R, Gulbrandsen A K (1995) Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5: 215-223
53. Stormer E, von Moltke L L, Shader R I, Greenblatt D J (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28: 1168-1175
54. Syvanen A C (2005) Toward genome-wide SNP genotyping. Nat Genet 37 (suppl.): S5-S10
55. Tabor H K, Risch N J, Myers R M (2002) Opinion: candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 3: 391-397
56. Taillon-Miller P, Saccone S F, Saccone N L, Duan S, Kloss E F, Lovins E G, Donaldson R, Phong A, Ha C, Flagstad L, Miller S, Drendel A, Lind D, Miller R D, Rice J P, Kwok P Y (2004) Linkage disequilibrium maps constructed with common SNPs are useful for first-pass disease association screens. Genomics 84: 899-912
57. Timmer C J, Sitsen J M, Delbressine L P (2000) Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38: 461-474
58. Wang W Y, Barrait B J, Clayton D G, Todd J A (2005) Genome-wide association studies: theoretical and practical concerns. Nature reviews. Genetics 6: 109-118
59. Wheeler D L, Barrett T, Benson D A, Bryant S H, Canese K, Church D M, DiCuccio M, Edgar R, Federhen S, Helmberg W, Kenton D L, Khovayko O, Lipman D J, Madden T L, Maglott D R, Ostell J, Pontius J U, Pruitt K D, Schuler G D, Schriml L M, Sequeira E, Sherry S T, Sirotkin K, Starchenko G, Suzek T O, Tatusov R, Tatusova T A, Wagner L, Yaschenko E (2005) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 33: D39-D45
60. Wilson K, Mottram P, Sivanranthan A, Nightingale A (2001) Antidepressant versus placebo for depressed elderly. Cochrane Database Syst Rev: CD000561
61. Yesavage J A, Brink T L, Rose T L, Lum O, Huang V, Adey M, Leirer V O (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiat Res 17: 37-49
62. Yue Q Y, Zhong Z H, Tybring G, Dalen P, Dahl M L, Bertilsson L, Sjoqvist F (1998) Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 64: 384-390
63. Zanger U M, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23-37